IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
News
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline…
Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment…
Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment…
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo”…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education…
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education…
LifeSci Consulting Expands with Global Operations Consulting Capability and London Office
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — LifeSci Consulting, a boutique strategy consulting and…
LifeSci Consulting Expands with Global Operations Consulting Capability and London Office
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) — LifeSci Consulting, a boutique strategy consulting and…
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from…
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from…
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a…